Spero Therapeutics Expects To Provide Phase 2a Topline Proof Of Concept Data From SPR720 Program; Co. Also Initiated Dosing In PIVOT-PO Phase 3 Trial And Is Entitled To Receive $95M In Milestones As Part Of License Agreement

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!